Skip to content

Biolizin for Improving Functional Poor Appetite in Children Aged 6 to 36 Months (CTBE2502)

A Parallel-Group, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of a Zinc-Containing Dietary Supplement (Biolizin) in Improving Functional Poor Appetite in Children Aged 6 to 36 Months

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07153549
Acronym
CTBE2502
Enrollment
110
Registered
2025-09-04
Start date
2025-09-20
Completion date
2026-04-30
Last updated
2026-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Appetite Disorders, Feeding and Eating Disorders of Childhood, Functional Poor Appetite

Keywords

functional poor appetite, pediatric feeding problems, feeding difficulty, loss of appetite, eating/feeding behavior, Children's Eating Behaviour Questionnaire, toddler, infants, zinc supplement, dietary supplement, Biolizin

Brief summary

Functional poor appetite is common in young children and may be linked to suboptimal micronutrient intake and feeding behavior. This study evaluates whether a zinc-containing oral supplement (Biolizin syrup) can improve eating behavior in children aged 6 to 36 months who have poor appetite without an identifiable medical cause. Participants are followed for 42 days with clinic visits at Day 0, Day 7, Day 21, and Day 42. Caregivers complete validated questionnaires about feeding difficulties and eating behavior; the child's weight and length/height are measured at each visit. Safety is assessed through review of adverse events and routine laboratory tests; serum zinc may be measured according to the protocol. The primary outcome is the change from baseline to Day 42 in the total score of a validated feeding-difficulty scale. Secondary outcomes include changes in Children's Eating Behaviour Questionnaire (CEBQ) subscales, WHO growth indices, serum zinc (if measured), and overall safety

Detailed description

Poor appetite in toddlers often reflects a combination of nutritional and behavioral factors. Zinc is an essential trace element that contributes to taste perception, mucosal integrity, and appetite regulation; suboptimal zinc status may exacerbate reduced intake and feeding problems. Biolizin is an oral zinc-containing supplement intended to support appetite and healthy feeding behavior in young children. The study aims to determine whether the supplement, provided together with standardized caregiver counseling on responsive feeding practices, improves caregiver-reported feeding difficulty and eating behavior over 42 days. After consent and screening, eligible children attend visits at Day 0, Day 7 (±2), Day 21 (±3), and Day 42 (±4). At each visit, clinicians review medical history and concomitant treatments, record anthropometrics, and caregivers complete a validated Vietnamese feeding-difficulty scale (0-24, higher scores indicate worse difficulty) and the CEBQ subscales. The study product is taken orally per age-based dosing specified in the protocol; adherence is checked using dosing diaries and returned bottle counts where applicable. Safety laboratories (e.g., complete blood count, liver and renal chemistry) are planned at baseline and Day 42; serum zinc may be obtained according to protocol. Adverse events are collected from consent through Day 42 and are managed according to clinical judgment; expected reactions are generally mild (for example, gastrointestinal discomfort, taste changes, or rash). Source data are recorded in case report forms and entered into a secure database with audit trails, and only de-identified data are used for analysis or sharing. The study has ethics approval and written informed consent is obtained from caregivers before any procedures.

Interventions

DIETARY_SUPPLEMENTBiolizin

Oral zinc-containing syrup taken per age-based dosing specified in the protocol, once or twice daily for 42 consecutive days. Product is dispensed at baseline (with refill if needed); batch and expiry are recorded. Caregivers receive instructions for use and complete dosing diaries; adherence is checked by diary review and returned bottle counts. Concomitant zinc products or pharmacologic appetite stimulants are not allowed. Safety is monitored through adverse event review and routine laboratory tests at baseline and Day 42.

BEHAVIORALStandardized caregiver counseling on responsive feeding

Structured counseling delivered to caregivers at each clinic visit (Day 0, Day 7, Day 21, Day 42). Content includes mealtime routines, recognizing hunger/satiety cues, age-appropriate portions and textures, repeated exposure to diverse foods, and strategies to manage refusal or prolonged meals. A brief checklist guides delivery to ensure consistency across visits. No dietary supplement is provided in this intervention.

Sponsors

Haiphong University of Medicine and Pharmacy
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Masking description

Not applicable (open-label)

Intervention model description

Two groups: zinc-containing oral supplement (Biolizin) plus standardized caregiver counseling versus counseling only; follow-up for 42 days; age-stratified randomization (6-12 vs 13-36 months)

Eligibility

Sex/Gender
ALL
Age
6 Months to 36 Months
Healthy volunteers
No

Inclusion criteria

* Age 6 to 36 months at screening. * Functional poor appetite for ≥2 weeks with at least one of the following: * Clearly reduced intake versus usual (lower amount of food and/or fewer meals per day); * Prolonged meal duration (\>30 minutes per meal); * Refusal or avoidance of familiar foods previously accepted; * Oppositional feeding behaviors (turning away, crying, gagging/retching, prolonged food holding, lack of cooperation during meals). * No obvious organic cause of poor appetite (e.g., acute infection, gastrointestinal/metabolic disease). * Weight not below -2 SD compared with WHO growth standards. * Parent/guardian provides written informed consent.

Exclusion criteria

* Ongoing acute or chronic illnesses that can affect intake or absorption, including but not limited to: * Acute infections (e.g., tonsillitis, pneumonia, otitis media, viral febrile illness, acute diarrhea); * Chronic conditions affecting digestion or metabolism (e.g., celiac disease, malabsorption syndromes, chronic liver disease, chronic kidney disease, diabetes). * Neurodevelopmental or neurological conditions that impair feeding (e.g., cerebral palsy, autism spectrum disorder, global developmental delay). * Current or recent use of medications known to alter appetite or digestion/absorption (e.g., systemic corticosteroids, antiepileptics, prolonged antibiotics). * Use of zinc-containing products or other appetite stimulants within 7 days before screening. * Known hypersensitivity to any component of the study product. * Malabsorption, severe malnutrition, or requirement for specialized nutrition, including: * Confirmed or suspected malabsorption (e.g., celiac disease, severe lactose intolerance, short bowel syndrome, inflammatory bowel disease); * Severe malnutrition per WHO criteria (e.g., weight-for-length Z-score \< -3 SD, nutritional edema, marked loss of subcutaneous fat/muscle); * Physician-prescribed specialized nutrition plans (therapeutic formulas for cow's milk protein allergy, severe malnutrition, tube feeding, or individualized nutrition regimens beyond usual diet). * Nonadherent caregiver or high risk of loss to follow-up as judged by the investigator.

Design outcomes

Primary

MeasureTime frameDescription
Change in Children's Eating Behaviour Questionnaire (CEBQ) Composite Total Score from Baseline to Day 42Baseline to Day 42The CEBQ is a validated parent-reported questionnaire assessing eating behaviors in children. Each item is scored from 1 (never) to 5 (always). The composite total score is derived from multiple domains (range: 1-5). Higher scores indicate more adverse eating behaviors (worse outcome). A negative change (Day 42 - Baseline \< 0) indicates improvement.
Change in Children's Eating Behaviour Questionnaire (CEBQ) Food Approach Behaviors from Baseline to Day 42Baseline to Day 42The Children's Eating Behaviour Questionnaire (CEBQ) is a validated parent-reported questionnaire assessing eating behaviors in children. The "food approach" score is the mean of four subscales: Enjoyment of Food, Food Responsiveness, Emotional Overeating, and Desire to Drink. Each item is scored from 1 (never) to 5 (always). Subscale scores range from 1-5, with higher values indicating greater food approach behaviors (worse outcome). A negative change indicates improvement.
Change in Children's Eating Behaviour Questionnaire (CEBQ) Food Avoidant Behaviors from Baseline to Day 42Baseline to Day 42Mean change in Children's Eating Behaviour Questionnaire (CEBQ) "food avoidant" subscales (Satiety Responsiveness, Slowness in Eating, Food Fussiness, Emotional Undereating). Lower scores indicate less avoidance; negative change denotes improvement.
Responder Rate on Children's Eating Behaviour Questionnaire (CEBQ) (≥30% Improvement) at Day 42Day 42Proportion of participants achieving ≥30% decrease from baseline in the pre-specified Children's Eating Behaviour Questionnaire (CEBQ) adverse-behavior composite (per SAP).

Secondary

MeasureTime frameDescription
Change in Hoang Thi Bach Yen Anorexia Scale (Vietnamese Caregiver-Reported Pediatric Anorexia Scale) Total Score from Baseline to Day 42Baseline to Day 42The Hoang Thi Bach Yen Anorexia Scale (2020) is a validated Vietnamese caregiver-reported instrument to assess poor appetite in children. It includes 8 items covering mealtime characteristics (duration, amount of food intake) and eating behaviors (oppositional behavior, avoidance, food selectivity, food refusal). Each item is scored from 0 to 3 (0 = no symptom, 3 = severe symptom). The total score ranges from 0 to 24. Higher scores indicate worse appetite (more severe anorexia). Lower scores indicate better appetite. A negative change (Day 42 - Baseline \< 0) reflects clinical improvement.
Change in Body Weight from Baseline to Day 42Baseline to Day 42Body weight will be measured in kilograms (kg) at baseline and Day 42. The outcome is the mean change (Day 42 - Baseline). Weight-for-age Z-scores based on WHO growth standards may also be summarized descriptively.
Change in Number of Daily Meals from Baseline to Day 42Baseline to Day 42Caregiver-reported average number of meals per day over the prior week; outcome is change (Day 42 - Baseline).
Change in Mean Meal Duration from Baseline to Day 42Baseline to Day 42Caregiver-reported average minutes per meal over the prior week; outcome is change (Day 42 - Baseline).
Change in Caregiver-Rated Cooperation During Meals Scale Score from Baseline to Day 42Baseline to Day 42Caregiver-Rated Cooperation During Meals Scale is a study-specific, caregiver-reported measure of mealtime cooperation. The instrument uses a 5-point Likert scale ranging from 1 (very uncooperative) to 5 (very cooperative). Higher scores indicate better cooperation (favorable outcome). A positive change (Day 42 - Baseline \> 0) reflects improvement.
Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)From first dose to Day 42Number and proportion of participants with ≥1 TEAE; events characterized by system organ class/preferred term and graded by CTCAE v5.0. Collected using the study's standard ADR form.
Change in Serum Zinc Concentration from Baseline to Day 42Baseline to Day 42Serum zinc (µg/dL) measured per site laboratory procedures; outcome is change (Day 42 - Baseline).
Change in Body Length/Height from Baseline to Day 42Baseline to Day 42Body length (for children \<24 months) or standing height (for children ≥24 months) will be measured in centimeters (cm) at baseline and Day 42. The outcome is the mean change (Day 42 - Baseline). Length/height-for-age Z-scores based on WHO growth standards may also be summarized descriptively.

Countries

Vietnam

Contacts

CONTACTPhuong Thi Thu Nguyen, MD, PhD
nttphuong@hpmu.edu.vn+84936685007
CONTACTAnh Van Tran, MSc
tvanh@hpmu.edu.vn0343035492

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026